The latest cancer drugs news
Browsing: Cancer Drug News
FDA approves quizartinib for newly diagnosed acute myeloid leukaemia
On July 20, 2023, the Food and Drug Administration approved quizartinib with standard cytarabine and…
Cetuximab’s effectiveness and toxicity in advanced cutaneous squamous cell skin cancer
Treatment for locally advanced cutaneous squamous cell cancers (laCSCC) remains poorly defined. Most laCSCC tumours…
FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas
The Food and Drug Administration has granted accelerated approval to glofitamab-gxbm for relapsed or refractory…
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration has approved talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated…
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
The Food and Drug Administration has granted accelerated approval to epcoritamab-bysp for relapsed or refractory…
ICR-discovered drug to enter phase II clinical trial in ovarian cancer thanks to new research collaboration
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, UK,…
ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer
The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend…
Candidate cervical cancer drugs quickly evaluated using new model
Researchers at Oregon State University, USA, have created a means of speeding up and improving…
FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
On February 9, 2023, the Food and Drug Administration (FDA) approved dostarlimab-gxly for adult patients with…
FDA expands early breast cancer indication for abemaciclib with endocrine therapy
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib with endocrine therapy…